{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320095960576.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1600-6143.2006.01542.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-6143.2006.01542.x"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1600613522028775?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1600613522028775?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2006.01542.x/fullpdf"}},{"identifier":{"@type":"PMID","@value":"17049057"}}],"dc:title":[{"@value":"Beneficial Effects of Short-Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation"}],"description":[{"notation":[{"@value":"Clearance of hepatitis B surface antigen (HBsAg) by lamivudine is achieved in only a small proportion of patients with chronic hepatitis B virus (HBV) infection. We investigated the effect of lamivudine on de novo HBV reactivation after living-donor liver transplantation when the number of HBV was expected to be very small. Thirty-eight HBV-naive recipients who received liver grafts from antibodies to core antigen-positive donors receiving hepatitis B immunoglobulin (HBIG) were studied. HBsAg appeared in nine cases (23.7 %) despite receiving HBIG for 12-71 months (mean: 35.1 months) after transplantation. Lamivudine treatment was started in six recipients during the acute phase of HBV reactivation. Five of the six recipients achieved complete clearance of HBsAg in sera at a median of 4.6 months (ranging from 21 to 330 days) after lamivudine administration. Although lamivudine was stopped in four cases, all remained negative for HBsAg. Our findings suggested that short-term lamivudine treatment during acute phase of HBV reactivation could achieve complete clearance of HBsAg in a significant number of liver transplant recipients."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320095960579","@type":"Researcher","foaf:name":[{"@value":"M. Umeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960581","@type":"Researcher","foaf:name":[{"@value":"H. Marusawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960578","@type":"Researcher","foaf:name":[{"@value":"M. Ueda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960576","@type":"Researcher","foaf:name":[{"@value":"Y. Takada"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960580","@type":"Researcher","foaf:name":[{"@value":"H. Egawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960582","@type":"Researcher","foaf:name":[{"@value":"S. Uemoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320095960577","@type":"Researcher","foaf:name":[{"@value":"T. Chiba"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"16006135"}],"prism:publicationName":[{"@value":"American Journal of Transplantation"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2006-11","prism:volume":"6","prism:number":"11","prism:startingPage":"2680","prism:endingPage":"2685"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-6143.2006.01542.x"},{"@id":"https://api.elsevier.com/content/article/PII:S1600613522028775?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S1600613522028775?httpAccept=text/plain"},{"@id":"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2006.01542.x/fullpdf"}],"createdAt":"2006-10-18","modifiedAt":"2025-10-28","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Adolescent","dc:title":"Adolescent"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B","dc:title":"Hepatitis B"},{"@id":"https://cir.nii.ac.jp/all?q=Liver%20Transplantation","dc:title":"Liver Transplantation"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Lamivudine","dc:title":"Lamivudine"},{"@id":"https://cir.nii.ac.jp/all?q=Recurrence","dc:title":"Recurrence"},{"@id":"https://cir.nii.ac.jp/all?q=Child,%20Preschool","dc:title":"Child, Preschool"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Reverse%20Transcriptase%20Inhibitors","dc:title":"Reverse Transcriptase Inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Child","dc:title":"Child"},{"@id":"https://cir.nii.ac.jp/all?q=Retrospective%20Studies","dc:title":"Retrospective Studies"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004239680263168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"<i>De novo</i> activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1600-6143.2006.01542.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::3b90dedb9df29b5ffc14c39efc2e978f"},{"@type":"CROSSREF","@value":"10.3851/imp1771_references_DOI_EK4CpkAwnYj1QJCJAsE90suct9f"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_EK4CpkAwnYj1QJCJAsE90suct9f"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_EK4CpkAwnYj1QJCJAsE90suct9f"}]}